Member Info for wildbunch

Is back-with negativity-is he invested here-doubt it. Filtered.

Very good news. However, potential sources of funds will need to factor this news in-unless they were already privy to it. Not sure that 'end of summer' is feasible.

AMM, asked CFO at AGM before it started if their was any restriction on Sarepta remuneration being used to fund CDiff. He said that there was none except that Summit must fulfil their obligations regarding DMD development.

Hope you are right! Interesting-same meeting two contradictory impressions. Time will tell-fell that 100m grant is a big ask. Welcome money does not come for free-my understanding is that they in for biggish % for their current stake.

My understanding is that the CEO thinks we may well get some monies (perhaps government) that would not be dilutive but that it was unlikely we would get the whole 100m on that basis. In that case the remainder would almost certainly be dilutive-whether in the form of a share offering or a deal with a pharma.

Also at AGM. My impression was that there is little chance of non/dilutive deal.

Immediate concern is funding for C Diff. I was at AGM and expect news by end of September. Indian Summer was banter between Chairman and CEO. I would be surprised if some dilution did not happen. How much and on what terms is key. Why should investors buy more now when it might be cheaper tomorrow? Hoping for big news re next generation of DMD drug soonish. Think any t/o by Serepta will involve their paper plus cash sweetener. Elephant in room is DMD trial. Parents whose boys have finished trial can elect to continue dosing. Have they and what effect if any has been shown by the dosage to date. News may leak out do close knit DMD community and then to outside world. This could be good-or bad! Anyway, whatever happens in short term to share price is not material to LTH's-what matters is the effectiveness of the drugs-which we think we know re CDiff but are still in the dark re DMD. Incidentally, CFO is a nice guy, but by observation, should not be let anywhere near an investor presentation unless he is going to simply deal with financial issues. He is not a scientist and will come up against analysts with strong scientific background. Big investment houses employ such people and they recognise lack of expertise when they hear it. This does nothing do help the investment case. Goodnight.

Depends what offing means. See my note re AGM. Expected within weeks, end of summer, soon-take your pick!

Because I don't trade. Buy the rumour - sell the fact. Now waiting for inflection points-rest is background noise-who cares if it goes up or down 5p-or whether the US is 3p more than the UK. Goodnight..

Sorry. Their not there, Nasdaq not Aim! No bonus for me this year!

Agree strongly with GMCC. The execs get healthy base plus bonuses for achieving milestones etc, etc. Getting free shares (difference between vesting price and cash in price, I know) which attempts to align there interests with investors must have everything to do with substantial return to shareholders. As GMCC says this will mean either cash in tills because product(s) have got to market or the company has been sold or there has been a lucrative deal. Forget stuff like a listing on AIM, or recruiting high level execs, or meeting budgets-that's what they get paid a salary and a bonus for. Would be good if this could get passed on to the Rem C'tee. I am long term holder, I like the execs, incredibly worthy products-but lets get it straight-a free ride in share price appreciation from a historic fairly low level must be aligned to existing shareholders interests which they measure in cash not corporate objectives/milestones. God bless and goodnight.

Went. Some random notes All exec's in bullish mode both in session and individually.-much better position than last year. Received $60m from deal,advances with bothe products etc. Three near term inflection points. Expect news on non dilutive funding between variously, soon, weeks and end of summer. Will not be enough to cover all phase 3 financing. Are able to use deal money to part fund c diff phase 3 provided they meet their deal obligations re DMD. Believe that C Diff will be bigger than previously thought in return on investment-maybe only novel approach around at time of urgent need. Working on next generation of DMD formula. Very pleased with progress-not to distant future expect announcement of visible benefits. DMD 1st qtr 2018 results from phase out. DMD program fully recruited. Some boys have finished 48 week trial-parents have permission for them to continue taking drug-very disappointingly exec's did not know if amy had taken up this opportunity. (Noticed on previous occasions Summit present well on high level stuff-but not so hot on important practical detail) Got go ahead from 2 agencies for phase 3 c diff trials. Going for a superiority study-this means must demonstrate improvement on current best in class. Approach will lead to higher worth-if this is demonstrated. Cash in tills 2020/2021-asked same question 3 years ago-big subsequent drift-and fresh share options for GE since then! However, with the deal, and 3 near term inflection points future looks pretty good.

Wellcome Trust in it for about 20%.

Last e mail most relevant to SUMM that he/she has ever posted!

We may be happy to wait for returns-CEO probably would like to trouser £2m+ if he could get to to £6 sharpish. The only way to do this is to have great deal for C diff soon.

Sorry-4 should read share price of 50p

Done rough calculation. 1 If share price averages 20p (all old money) then benefit will be £705K 2 If share price averages 30p then benefit will be £2.2m 3 If share price averages 40p then benefit will be £4.125m 4 If share price averages 60p then benefit will be £6.18m Serious incentive do to a great deal before 10 March! Bon chance

See PLE. Creates hostility all over the place.

Top line results due in in Q2 2017. Thought we would know Q4 2016! No mention of any deal. Are they intending to go into phase 3 alone? Not reassuring.